fenazon-koffein 500 mg / 100 mg
orifarm healthcare a/s - fenazon / koffein - tablett - 500 mg / 100 mg
fenazon-koffein sterke 1 g / 100 mg
orifarm healthcare a/s - fenazon / koffein - tablett - 1 g / 100 mg
zeldox 80 mg
pfizer as - ziprasidonhydrokloridmonohydrat - kapsel, hard - 80 mg
zeldox 20 mg
pfizer as - ziprasidonhydrokloridmonohydrat - kapsel, hard - 20 mg
fanalgin 500 mg / 50 mg
karo pharma as - fenazon / koffein - tablett - 500 mg / 50 mg
zeldox 20 mg
orifarm as - ziprasidonhydrokloridmonohydrat - kapsel, hard - 20 mg
zeldox 40 mg
orifarm as - ziprasidonhydrokloridmonohydrat - kapsel, hard - 40 mg
zeldox 20 mg
orifarm as - ziprasidonhydrokloridmonohydrat - kapsel, hard - 20 mg
mekinist
novartis europharm limited - trametinib - melanom - antineoplastiske midler - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. non-small cell lung cancer (nsclc)trametinib i kombinasjon med dabrafenib er indisert for behandling av voksne pasienter med avansert non-small cell lung cancer med en braf v600 mutasjon.
tafinlar
novartis europharm limited - dabrafenib mesilate - melanom - antineoplastiske midler - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. adjuvant behandling av melanomadabrafenib i kombinasjon med trametinib er indikert for adjuvant behandling av voksne pasienter med stadium iii melanom med en braf v600 mutasjon, følgende komplett reseksjon. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.